City

Charlottesville (1)

Karachi (1)

Tyumen (1)

Condition

Menstrual Irregularities (3)

Hyperandrogenism (2)

Endometrial Pathology (1)

Morbid Obesity (1)

Polycystic Ovarian Syndrome (1)

Overall Status

Unknown status (2)

Completed (1)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 4 (1)

Sponsor

Dow University of Health Sciences (1)

Tyumen State Medical Academy (1)

University of Virginia (1)

Collaborator

Intervention

20 mcg ethinylestradiol /3 mg drospirenone (1)

20 mcg ethinylestradiol/3 mg drospirenone and selmevit (1)

30 mcg ethinylestradiol/3 mg drospirenone (1)

30 mcg ethinylestradiol/3 mg drospirenone and selmevit (1)

35 mcg ethinylestradiol/2 mg cyproterone (1)

35 mcg ethinylestradiol/2 mg cyproterone and selmevit (1)

tab metformin (1)

tab pioglitazone (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (3)

Study Type

Interventional (2)

Observational (1)

Menstrual Irregularities

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Menstrual Irregularities, Hyperandrogenism Trial in Karachi (TAB METFORMIN, TAB PIOGLITAZONE)

Unknown status

Menstrual Irregularities
Hyperandrogenism

TAB METFORMIN
TAB PIOGLITAZONE

Karachi, Sindh, Pakistan

Dow University Hospital OJHA

Nov 28, 2018

Menstrual Irregularities and Endometrial Pathology in Women

Completed

Morbid Obesity
+2 more

Charlottesville, Virginia

University of Virginia

May 29, 2015

Polycystic Ovarian Syndrome, Hyperandrogenism, Menstrual Irregularities Trial in Tyumen (20 mcg ethinylestradiol /3 mg

Unknown status

Polycystic Ovarian Syndrome
+2 more

20 mcg ethinylestradiol /3 mg drospirenone
+5 more

Tyumen, Russian Federation

Tyumen State Medical Academy

Nov 20, 2014